Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CCL2 | P13500 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194315 | 0.80 | KDM4E (0.38) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL4158909 | 0.77 | KDM4E (0.49) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL1268568 | 0.76 | ALDH1A1 (0.38) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL6510269 | 0.76 | KDM4E (0.36) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL15018068 | 0.76 | HEXA (0.41) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL20813226 | 0.74 | ALDH1A1 (0.40) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL11797517 | 0.74 | HEXA (0.40) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL8485186 | 0.73 | KDM4E (0.34) | NSD2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL15018655 | 0.72 | NR1I2 (0.47) | ALDH1A1KDM4EHPGDMAPTGAA | |
| SCHEMBL15018437 | 0.72 | HEXA (0.45) | NSD2ALDH1A1KDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| WO-2013087634-A2 | OXIDATIVE DYEING COMPOSITION COMPRISING A SPECIFIC PERIMIDINE COUPLER IN A MEDIUM WITH HIGH FATTY SUBSTANCE CONTENT, METHODS AND SUITABLE DEVICE | L'OREAL (FR) | 2013-06-20 | — | — | WO | claimed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | claimed |
| US-10844065-B2 | Heterocyclic compound, and organic electroluminescence device and organic electroluminescence display device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-11-24 | — | — | US | disclosed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | disclosed |
| EP-2190434-B1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20190084986-A1 | HETEROCYCLIC COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-03-21 | — | — | US | disclosed |
| EP-1306131-B1 | Cross-coupling process using a catalyst comprising a cyclic nitrogen ligand | SUMITOMO CHEMICAL CO (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| WO-2013087634-A2 | OXIDATIVE DYEING COMPOSITION COMPRISING A SPECIFIC PERIMIDINE COUPLER IN A MEDIUM WITH HIGH FATTY SUBSTANCE CONTENT, METHODS AND SUITABLE DEVICE | L'OREAL (FR) | 2013-06-20 | — | — | WO | disclosed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| US-20030162950-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-28 | — | — | US | disclosed |
| EP-1306131-A2 | Cross-Coupling catalyst comprising a cyclic nitrogen ligand and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-05-02 | — | — | EP | disclosed |
| EP-0985674-B1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR ALPHA-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING ALPHA-OLEFIN POLYMERS | MITSUBISHI CHEM CORP (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6255515-B1 | COORDINATION POLYMERIZATION CATALYSTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-0985674-A1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5922086-A | OXIDATION COLOR DYES FOR HAIR WITH PERMIDINE COUPLERS AND DEVELOPERS | CLARIANT GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| EP-0822804-A1 | HAIR COLORANTS BASED ON PERIMIDINE DERIVATIVES | Clariant GmbH (DE) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033692-A1 | HAIR COLORANTS BASED ON PERIMIDINE DERIVATIVES | CLARIANT GMBH (DE) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162950-A1 | Coupling catalyst and process using the same | NOD1, PYM1, C9 | NSD2 817/4885ALDH1A1 3293/4885KDM4E 3633/4885 |
| US-10844065-B2 | Heterocyclic compound, and organic electroluminescence device and organic electroluminescence display device including the same | CCND2, CCND1, ODC1 | NSD2 286/4885ALDH1A1 13/4885KDM4E 3336/4885 |
| US-20190084986-A1 | HETEROCYCLIC COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE INCLUDING THE SAME | CCND2, CCND1, ODC1 | NSD2 286/4885ALDH1A1 13/4885KDM4E 3336/4885 |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | NSD2 1355/4885ALDH1A1 3607/4885KDM4E 3292/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | NSD2 841/4885ALDH1A1 3774/4885KDM4E 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.